Treatment of small cell lung cancer: the Copenhagen experience.
Author(s): Hirsch FR, Dombernowsky P, Hansen HH
Affiliation(s): Department of Medical Oncology P, Bispebjerg Hospital, Copenhagen, Denmark.
Publication date & source: 1994-01, Anticancer Res., 14(1B):317-9.
Publication type: Clinical Trial; Comparative Study; Randomized Controlled Trial; Review
The present article is a review of recent treatment protocols for patients with small cell lung cancer (SCCL) treated in Copenhagen from 1985 to 1990. Furthermore, preliminary data on long-term survivors (> 5 years) from 9 treatment protocols since 1973 are reviewed. For 484 patients < or = 70 years old, no survival difference was observed between 2 platinum (cis-platinum or carboplatin) containing regimens, while the survival was better in these two induction regimens compared to an alternating control arm. For patients > 70 years old, Etoposide (VP-16) and Teniposide (VM-26) were compared in a randomized fashion. Both drugs were highly active, and no significant difference in activity was observed. All together 1527 patients have been included in clinical trials in the Copenhagen Lung Cancer Study Group since 1973. The rates of 5- and 10-years survivors were 3.5% and 1.8% respectively. Long-term survival can be achieved in all stages of SCCL.